ABOUT US
Funding psilocybin research for a better tomorrow
Founded by Carey and Claudia Turnbull, B. More is a 501(c)(3) non-profit, clinical-stage biopharmaceutical company on a mission to develop better treatment options for those struggling with alcoholism and other substance use disorders. Named after Claudia Turnbull’s brother, Brett Moore, who died of a drug overdose, B. More is focused on the development of psychedelic medicines that offer the potential to dramatically improve the lives of those for whom current treatment options have proven ineffective. With a long history of partnership with researchers at the NYU School of Medicine, B. More is advancing clinical research to help these individuals and their loved ones live a better tomorrow.
Founders
Founders
AboutOUR FUNDERS
Together we can change lives
The work of B. More would not be possible without the generous support of our funders: Andrew Mason, Alan Fournier, Cody Swift, George Sarlo, Dr. Bronner’s Soap, Claudia and Carey Turnbull, the Evolve Foundation and others. We invite you to join the effort in making a better tomorrow a reality for those struggling with alcoholism and other substance use disorders.
OUR FOUNDER
Carey Turnbull
Founder & CEO
Carey Turnbull has over a decade of experience in early-stage drug development for half a dozen companies variously as an investor, founder, and CEO. An early philanthropic donor supporting psychedelic science and research, Carey has been at the forefront of driving the psychedelic renaissance and the development of better treatment options for those suffering from psychiatric and neurological disorders.
In addition to his roles as Founder and CEO of B. More and Ceruvia Lifesciences, Carey is the chair of the advisory board to NYU’s Center for Psychedelic Medicine, board member and president of the Heffter Research Institute.
CHIEF OPERATIONS OFFICER
Paul Bezodis
COO
Paul is a seasoned freelance clinical research professional bringing over 25 years of global experience across all phases of human trials. He has contributed to top-tier pharmaceutical companies, pioneering biotech firms, and both large-scale and boutique contract research organizations.
For the past four years, Paul has been leading the team and the European program at MAPS Europe B.V. Chief among his achievements at MAPS Europe was the completion of the first ever European phase 2 trial for MDMA-assisted therapy (MDMA‑AT) for post-traumatic stress disorder (PTSD).
For the past four years, Paul has been leading the team and the European program at MAPS Europe B.V. Chief among his achievements at MAPS Europe was the completion of the first ever European phase 2 trial for MDMA-assisted therapy (MDMA‑AT) for post-traumatic stress disorder (PTSD).
BOARD OF DIRECTORS
Alan Fournier
Founder, Pennant Investors
Cody Swift
Executive Director, Riverstyx Foundation
Carey Turnbull
Co-founder and CEO, B. More
Claudia Turnbull